Yervoy (ipilimumab) / Ono Pharma, BMS  >>  Phase 3
Welcome,         Profile    Billing    Logout  

52 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yervoy (ipilimumab) / BMS
ACTRN12620001199909: DREAM3R: A phase 3 trial of durvalumab with chemotherapy as first line treatment in mesothelioma

Recruiting
3
480
 
University of Sydney, AstraZeneca Pty Ltd
Pleural Mesothelioma (PM)
 
 
CheckMate 067, NCT01844505 / 2012-005371-13: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma

Checkmark Data from P3 CheckMate 067 trial in 1L advanced melanoma
Sep 2021 - Sep 2021: Data from P3 CheckMate 067 trial in 1L advanced melanoma
Checkmark From CheckMate 067 trial in combination with Yervoy for melanoma at ASCO 2021
Jun 2021 - Jun 2021: From CheckMate 067 trial in combination with Yervoy for melanoma at ASCO 2021
Checkmark Six and half year follow-up data from CheckMate 067 study in combination with Yervoy for advanced melanoma at ASCO 2021
More
Active, not recruiting
3
1296
Europe, Canada, US, RoW
Nivolumab, BMS-936558, MDX-1106, Ipilimumab, Yervoy, BMS-734016, MDX-010, Placebo for Nivolumab, Placebo for Ipilimumab
Bristol-Myers Squibb
Unresectable or Metastatic Melanoma
08/16
10/24
2016-005197-35: A clinical trial to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab for patients with melanoma that has been successfully treated with surgery but has a high probability of coming back.

Not yet recruiting
3
1378
Europe
Pembrolizumab, Interferon alfa-2b, MK-3475, Solution for infusion, Solution for injection/infusion, KEYTRUDA®, IntronA
Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland, SWOG
High risk resected melanoma., Melanoma, which, although it has been successfully treated with surgery, has a high probability of coming back., Diseases [C] - Cancer [C04]
 
 
CheckMate 214, NCT02231749 / 2014-001750-42: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Checkmark Presentation of data from CheckMate 214 trial in advanced Sarcomatoid RCC at IKCS 2022
Nov 2022 - Nov 2022: Presentation of data from CheckMate 214 trial in advanced Sarcomatoid RCC at IKCS 2022
Checkmark Additional data following 42-month period in combination with Yervoy in advanced 1L RCC from CheckMate 214 study
Jan 2022 - Jan 2022: Additional data following 42-month period in combination with Yervoy in advanced 1L RCC from CheckMate 214 study
Checkmark Additional data following 42 month randomization from CheckMate-214 trial for advanced 1L RCC
More
Active, not recruiting
3
1390
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, Yervoy, Sunitinib, Sutent
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
06/17
08/27
CheckMate 238, NCT02388906 / 2014-002351-26: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Hourglass Oct 2023 - Oct 2023 : Seven-year efficacy results from P3 CheckMate-238 trial of adjuvant Opdivo in resected stage III/IV melanoma at ESMO 2023
Checkmark Data from CheckMate -238 trial in resected stage III/IV melanoma at ESMO 2019
Sep 2019 - Sep 2019: Data from CheckMate -238 trial in resected stage III/IV melanoma at ESMO 2019
Checkmark In patients with resected stage III or IV melanoma
Jun 2018 - Jun 2018: In patients with resected stage III or IV melanoma
More
Active, not recruiting
3
906
Europe, Canada, Japan, US, RoW
Ipilimumab, Nivolumab, Placebo matching Ipilimumab, Placebo matching Nivolumab
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Melanoma
11/18
10/24
E1609, NCT01274338 / 2011-004257-29: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Checkmark From E1609 study for resected high-risk melanoma
Mar 2020 - Mar 2020: From E1609 study for resected high-risk melanoma
Checkmark Data from P3 study of adjuvant ipilimumab vs. high-dose interferon alfa-2b for resected high-risk melanoma
Dec 2019 - Dec 2019: Data from P3 study of adjuvant ipilimumab vs. high-dose interferon alfa-2b for resected high-risk melanoma
Checkmark From 029 study for melanoma at ASCO 2014
More
Active, not recruiting
3
1673
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI), Bristol-Myers Squibb, National Cancer Institute
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/19
03/25
CheckMate 143, NCT02017717 / 2013-003738-34: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

Checkmark Data from CheckMate-143 trial vs bevacizumab in 2L glioblastoma
May 2020 - May 2020: Data from CheckMate-143 trial vs bevacizumab in 2L glioblastoma
Checkmark From CheckMate-143 trial in 2L glioblastoma
Jun 2017 - Jun 2017: From CheckMate-143 trial in 2L glioblastoma
Checkmark ASCO 2016
More
Active, not recruiting
3
529
Europe, US, RoW
Nivolumab, BMS-936558, Bevacizumab, Avastin, Ipilimumab, Yervoy
Bristol-Myers Squibb
Recurrent Glioblastoma
06/19
04/24
CheckMate 9LA, NCT03215706 / 2017-001195-35: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Checkmark Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
More
Active, not recruiting
3
719
Europe, Canada, Japan, US, RoW
Ipilimumab, Yervoy, BMS734016, Nivolumab, Opdivo, BMS936558, Carboplatin, Paclitaxel, Taxol, Pemetrexed, Alimta, Cisplatin, Platinol
Bristol-Myers Squibb
Non-Small Cell Lung Cancer
08/19
01/26
Lung-Map Sub-Study, NCT02785952: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Active, not recruiting
3
275
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
12/19
04/25
CheckMate 9ER, NCT03141177 / 2017-000759-20: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Hourglass Jun 2023 - Jun 2023 : 3 year quality-of-life follow-up data from CheckMate -9ER trial in 1L RCC at ASCO 2023
Checkmark Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Jun 2022 - Jun 2022: Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Checkmark Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
Jun 2022 - Jun 2022: Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
More
Active, not recruiting
3
701
Europe, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Cabozantinib, Cabometyx, Sunitinib, Sutent, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb, Exelixis, Ono Pharmaceutical Co. Ltd
Renal Cell Carcinoma
02/20
04/24
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
CheckMate 649, NCT02872116 / 2016-001018-76: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Checkmark Data from Checkmate-649 trial in advanced or metastatic gastric or gastroesophageal junction cancer at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from Checkmate-649 trial in advanced or metastatic gastric or gastroesophageal junction cancer at ASCO-GI 2023
Checkmark From CheckMate-649 study in combination with chemo in the Chinese subgroup of adv/mets gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Apr 2021 - Apr 2021: From CheckMate-649 study in combination with chemo in the Chinese subgroup of adv/mets gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Checkmark Data from Checkmate-649 trial in combination with Yervoy for advanced or metastatic gastric or gastroesophageal junction cancer at ESMO 2020
More
Active, not recruiting
3
2031
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
05/20
05/24
2019-002790-58: A study of nivolumab and ipilimumab in combination with Transarterial ChemoEmbolization (TACE) in participants with intermediate stage liver cancer (CheckMate 74W)

Not yet recruiting
3
765
Europe, RoW
NIVOLUMAB - 10mL vial (COMMERCIAL), NIVOLUMAB - 4mL vial (COMMERCIAL), IPILIMUMAB (200mg / 40ml vial), IPILIMUMAB (50mg / 10ml vial), BMS-936558, BMS-734016, Concentrate for solution for infusion, Opdivo (100 mg/10 ml), Opdivo (40 mg/4 ml)
Bristol-Myers Squibb International Corporation, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation
Intermediate-stage Hepatocellular Carcinoma (HCC), Intermediate-stage Liver Cancer, Diseases [C] - Cancer [C04]
 
 
2020-002821-28: Study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype Etude d'efficacité du nivolumab + ipilimumab versus pazopanib seul chez des patients atteints d’un sous-type rare de sarcome avancé non résécable ou métastatique

Not yet recruiting
3
96
Europe
Nivolumab, Ipilimumab, Pazopanib, Solution for injection, Film-coated tablet, Opdivo, Yervoy, Votrient
Centre Léon Bérard, BMS
Metastatic or unresectable advanced rare sarcomas Sarcomes rares avancés non résécables ou métastatiques, Metastatic advanced rare sarcomas Sarcomes rares avancés métastatiques, Diseases [C] - Cancer [C04]
 
 
CheckMate 648, NCT03143153 / 2016-001514-20: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Checkmark Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Checkmark Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
May 2022 - May 2022: Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
Checkmark Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for 1L ESCC based on Checkmate-648 trial
More
Active, not recruiting
3
970
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558 (Nivolumab), Opdivo (Nivolumab), Ipilimumab, BMS-734016 (Ipilimumab), Yervoy (Ipilimumab), Cisplatin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Various Advanced Cancer
01/21
01/25
eNERGY, NCT03351361 / 2017-002842-60: Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients

Completed
3
217
Europe
Nivolumab + Ipilimumab, Chemotherapy
Rennes University Hospital
Advanced Non Small Cell Lung Cancer
07/21
07/22
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
COSMIC-313, NCT03937219 / 2018-004567-31: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Feb 2023 - Dec 2023: Overall survival analysis data from COSMIC-313 trial in combination with opdivo and yervoy for advanced 1L RCC
Checkmark Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
Sep 2022 - Sep 2022: Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
Checkmark Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
Sep 2022 - Sep 2022: Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
More
Active, not recruiting
3
840
Europe, Canada, US, RoW
Cabozantinib, Cabometyx, XL184, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Cabozantinib-matched placebo
Exelixis
Renal Cell Carcinoma
01/22
03/25
NCT02278887 / 2013-005406-54: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Active, not recruiting
3
168
Europe
Translational research, tumor tissue, blood, Cyclophosphamide, chemotherapy, Fludarabine, Interleukin-2, Proleukin, Ipilimumab infusion, standard treatment
The Netherlands Cancer Institute, Copenhagen University Hospital at Herlev
Metastatic Melanoma
09/22
06/27
EMPOWER-Lung 3, NCT03409614 / 2017-001311-36: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Checkmark Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
Oct 2022 - Oct 2022: Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
Checkmark OS and PFS data from trial for NSCLC at ESMO 2021
Sep 2021 - Sep 2021: OS and PFS data from trial for NSCLC at ESMO 2021
Checkmark From trial for NSCLC
More
Active, not recruiting
3
790
Europe, US, RoW
REGN2810, cemiplimab, REGN2810/chemo/ipi, Chemotherapy, Placebo
Regeneron Pharmaceuticals, Sanofi
Non-small Cell Lung Cancer
02/25
02/25
CheckMate 914, NCT03138512 / 2016-004502-34: A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

Calendar Jan 2024 - Dec 2024: Data readout from part B of CheckMate 914 trial in combination with Yervoy for adjuvant RCC
Hourglass Sep 2023 - Mar 2024 : H2 FY'23 - Filing in Japan in combination with Yervoy for adjuvant RCC based on CheckMate-914 trial
Hourglass Jan 2022 - Dec 2022 : Regulatory submission in Japan in combination with Opdivo for adjuvant RCC (based on CheckMate-914 trial)
Checkmark Data from CheckMate 914 trial in combination with Yervoy for adjuvant RCC at ESMO 2022
Sep 2022 - Sep 2022: Data from CheckMate 914 trial in combination with Yervoy for adjuvant RCC at ESMO 2022
More
Completed
3
1653
Europe, Canada, Japan, US, RoW
nivolumab, Opdivo, ipilimumab, Yervoy, nivolumab placebo, ipilimumab placebo
Bristol-Myers Squibb
Carcinoma, Renal Cell
09/23
02/24
SWOG S1404, NCT02506153: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Active, not recruiting
3
1345
Europe, Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
09/23
01/25
DICIPLE, NCT03469960 / 2017-002540-33: Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Active, not recruiting
3
265
Europe
Ipilimumab, Nivolumab
Intergroupe Francophone de Cancerologie Thoracique
Non-Small Cell Lung Cancer Metastatic
11/23
12/24
CheckMate 74W, NCT04340193: A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

Terminated
3
26
Europe, Canada, Japan, US, RoW
nivolumab, Opdivo, BMS-936558, ipilimumab, Yervoy, TACE
Bristol-Myers Squibb
Cancer, Hepatocellular
12/23
12/23
CheckMate 901, NCT03036098 / 2016-003881-14: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Calendar Jan 2024 - Dec 2024: Data readout from CheckMate 901 trial in combination with Yervoy for cis-ineligible 1L urothelial cancer
Mar 2023 - Mar 2024: Submission in Japan in combination with chemotherapy for 1L urothelial cancer (based on CheckMate-901 trial)
Hourglass Jan 2023 - Dec 2023 : Submission in Japan in combination with Opdivo for 1L urothelial cancer (based on CheckMate-901 trial)
Feb 2023 - Dec 2023: Data readout from CheckMate 901 trial in combination with Yervoy for cis-eligible 1L urothelial cancer
Hourglass Oct 2023 - Oct 2023 : OS and PFS data from P3 CheckMate-901 trial in 1L unresectable or metastatic urothelial carcinoma at ESMO 2023
More
Active, not recruiting
3
1290
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Gemcitabine, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Urothelial Cancer
10/24
06/28
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
CA209-8Y8, NCT03873402 / 2018-004695-35: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Hourglass Jul 2022 - Dec 2022 : Data readout from P3 CA209 -8Y8 trial for 1L RCC
Active, not recruiting
3
437
Europe, US, RoW
Nivolumab, Opdivo, Ipilimumab, Yervoy, Ipilimumab placebo
Bristol-Myers Squibb
Renal Cell Carcinoma
04/24
03/25
IMSTAR-HN, NCT03700905 / 2016-004758-13: Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Active, not recruiting
3
276
Europe
Surgical resection of primary tumor, Adjuvant radio(-chemo)therapy, Neoadjuvant Nivolumab, Adjuvant Nivolumab, Adjuvant Nivolumab and Ipilimumab
Universitätsklinikum Hamburg-Eppendorf, University Hospital, Essen, Westpfalz-Clinical Center GmbH, Charite University, Berlin, Germany
Head and Neck Cancer
05/24
05/24
CheckMate 227, NCT02477826 / 2014-003630-23: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Checkmark Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Checkmark From CheckMate 227 trial in combination with Yervoy for NSCLC at ASCO 2021
More
Active, not recruiting
3
2748
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, Ipilimumab, Yervoy, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non-Small Cell Lung Cancer
08/24
08/24
PDIGREE, NCT03793166: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The Study

Checkmark Initiated in combination with nivolumab and ipilimumab for 1L RCC
Jan 2019 - Jan 2019: Initiated in combination with nivolumab and ipilimumab for 1L RCC
Active, not recruiting
3
1175
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/24
09/24
DREAMseq, NCT02224781: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Active, not recruiting
3
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
12/24
12/24
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Recruiting
3
96
Europe
Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
Centre Leon Berard
Sarcoma
02/25
08/25
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
04/25
12/25
CheckMate 8HW, NCT04008030 / 2018-000040-26: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Calendar Jan 2024 - Dec 2024: Data readout from P3 CheckMate 8HW trial for 1L+ MSI High CRC
Jan 2023 - Dec 2023: Submission in Japan in combination with Yervoy for 1L colorectal cancer (based on CHECKMATE 8HW trial)
Jan 2023 - Dec 2023: Submission in Japan in combination with Opdivo for 1L colorectal cancer (based on CHECKMATE 8HW trial)
Recruiting
3
831
Europe, Canada, Japan, US, RoW
Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Metastatic Colorectal Cancer
06/25
06/26
CheckMate 73L, NCT04026412 / 2019-001222-98: A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Calendar Jan 2025 - Dec 2025: Data from CheckMate73L trial in combination with Yervoy and Imfinzi for unresectable stage III NSCLC
Hourglass Jul 2018 - Dec 2018 : In 1L TMB-high NSCLC
Hourglass Jul 2018 - Dec 2018 : In 1L TMB-high NSCLC
Active, not recruiting
3
888
Europe, Canada, Japan, US, RoW
nivolumab, ipilimumab, durvalumab
Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
LONESTAR, NCT03391869: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Recruiting
3
400
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Local Consolidation Therapy, LCT, Local Consolidative Therapy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
12/25
12/25
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Recruiting
3
190
Europe
Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment
ETOP IBCSG Partners Foundation, USZ Foundation
Non-Small Cell Lung Cancer, Melanoma
01/26
12/26
CheckMate 9DW, NCT04039607 / 2019-000252-34: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Calendar Jan 2025 - Dec 2025: Data readout from CheckMate 9DW trial for 1L HCC
Hourglass Jan 2020 - Jun 2020 : Submission in Japan for 2L ovarian cancer
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Nivolumab, Ipilimumab, Sorafenib, lenvatinib
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Hepatocellular Carcinoma
09/26
09/26
NCT04157985: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Recruiting
3
578
US
Continue PD-1/PD-L1 Inhibitors treatment, Keytruda (pembrolizumab), Optiva (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), LIBTAYO (cemiplimab), Discontinue PD-1/PD-L1-1 inhibitor
Jason J. Luke, MD
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
10/28
10/28
NCT05144854: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active, not recruiting
3
626
Japan, RoW
ONO-4538, Nivolumab, Opdivo, Ipilimumab, BMS-734016, Yervoy, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium
Ono Pharmaceutical Co. Ltd
Gastric Cancer
02/27
05/27
eVOLVE-Meso, NCT06097728: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Volrustomig, MEDI5752, Pemetrexed, Alimta, Carboplatin, Paraplatin, Cisplatin, Platinol, Nivolumab, Opdivo, Ipilimumab, Yervoy
AstraZeneca
Unresectable Pleural Mesothelioma
03/27
03/28
2019-003454-83: Does adding double immunotherapy to the combination of chemotherapy and radiotherapy result in a better anti-tumor efficacy?

Ongoing
2/3
29
Europe
Concentrate and solvent for solution for injection/infusion, , Ipilimumab, nivolumab
Amsterdam UMC, VU University Medical Center, BMS
locally advanced non-small cell lung cancer, lung cancer which is confined to the chest on 1 side and which has not spread to the rest of the body, Diseases [C] - Cancer [C04]
 
 
CA209-9HX, NCT03879122 / 2017-004377-13: A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting
2/3
135
Europe
Ipilimumab 5 MG/ML, YERVOY, Nivolumab 10 MG/ML, Opdivo, Docetaxel, ADT (androgen deprivation therapy)
Spanish Oncology Genito-Urinary Group, Syntax for Science, S.L, Bristol-Myers Squibb
Metastatic Hormone-sensitive Prostate Cancer
07/23
12/24
NCT04887870: Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Active, not recruiting
2/3
55
US
Sitravatinib, MGCD516, Nivolumab, OPDIVO, Pembrolizumab, KEYTRUDA, Enfortumab Vedotin-Ejfv, PADCEV, Ipilimumab, YERVOY
Mirati Therapeutics Inc.
Advanced or Metastatic Solid Malignancies
04/25
04/25
NRG-BN007, NCT04396860: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Active, not recruiting
2/3
159
US
Contrast-enhanced Magnetic Resonance Imaging, CONTRAST ENHANCED MRI, Contrast-enhanced MRI, MRI With Contrast, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, NovoTTF-100A Device, NovoTTF-100A, NovoTTF-100A System, NovoTTF-100A system (Optune), NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI), NRG Oncology
Gliosarcoma, MGMT-Unmethylated Glioblastoma
04/23
03/25
FFCD 2101-PRODIGE 81, NCT05665348: Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Not yet recruiting
2/3
574
Europe
Ipilimumab Injection, Atezolizumab, Bevacizumab, Atezolizumab Injection
Federation Francophone de Cancerologie Digestive
HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
09/24
04/26
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
NCT04929041: Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

Recruiting
2/3
427
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/27
12/27
NCT02339571: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting
2/3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Elastography, MRE, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
06/33
06/33
NCT03755739: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Recruiting
2/3
200
RoW
Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy, Checkpoint inhibitor (CPI) such as Keytruda plus chemotherapy
Second Affiliated Hospital of Guangzhou Medical University
Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer, Cervical Cancer, Breast Cancer
11/33
11/36

Download Options